Drug Trial Radar · NCT07758985
Safety, Tolerability, Pharmacokinetics, and Mosquitocidal Activity of Lotilaner in Healthy Participants in Mali.
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Sep 14, 2026
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Medicines for Malaria VentureAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Radboud University Medical Center; London School of Hygiene and Tropical Medicine; Malaria Research and Training Center, Bamako, Mali
- First posted
- Aug 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1b, single-cente, randomized, double-blind, placebo-controlled proof-of-concept study evaluating the safety, tolerability, pharmacokinetics and mosquitocidal activity of single oral doses of lotilaner in healthy, adult participants living in Mali.
Conditions
- Malaria
Interventions
Cohort 1 low dose lotilaner with a high-fat mealDrug
Participants will receive a single low dose of lotilaner with a high-fat meal
Cohort 1 low dose placebo with a high-fat mealOther
Participants will receive a single low dose of placebo with a high-fat meal
Cohort 2 high dose lotilaner in fasted stateDrug
Participants will receive high dose lotilaner in a fasted state
Cohort 2 high dose placebo in fasted stateOther
Participants will receive a single high dose of placebo in a fasted state
Cohort 3 high dose lotilaner with a high-fat mealDrug
Participants will receive a single high dose of lotilaner after a high-fat meal
Cohort 3 high dose placebo with a high-fat mealOther
Participants with receive a single high dose of placebo with a high-fat meal
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of LotilanerTime frame: From hour 0 on Day 1 through the end of the study (Day 169)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Malaria Research and Training Center
Bamako, Mali · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.